We are pleased to announce that the 2024 Symposium Travel Awards Program is now accepting applications to support attendance by individuals who could not participate in the Symposium without financial support.
Launched in 2007, the program is part of our commitment to making this important event…
We are thrilled to share that Suzanne McGurn, President and CEO, was presented with the Public Sector Leadership Award by the Canadian Organization for Rare Disorders (CORD). The award recognizes outstanding leadership and service as a public officer over multiple years across several agencies and…
Last year, CADTH communicated several improvements to our drug reimbursement review program, including a Lean review to identify process enhancements. We undertook this work as part of our commitment to continuous improvement and to advance our strategic ambitions to anticipate, innovate, and…
CADTH is working with a group of international health technology assessment (HTA) organizations to share learnings about the development of economic models that consider disease pathways.
Globally, HTA organizations are seeing a growing number of drugs available for the same disease area. This can…
We are proud and excited to share that our organization has been named one of the National Capital Region's top employers for 2024. This special designation recognizes employers in the Ottawa-Gatineau area that lead their industries in offering exceptional places to work.
We were measured against…
Current consultation status: Closed Consultation period: January 25 to February 22, 2024
CADTH is taking steps to help drug sponsors enhance the budget impact analyses (BIAs) included in the submissions they file with our Drug Reimbursement Review program.
BIAs help decision-makers understand…
Call for Nominations: Expert and Advisory Committee Members
Coming Soon!
The 2024 call for nominations will be open from March 4, 2024, to April 2, 2024. Please note the dates and length of the nominations window this year.
CADTH recognizes that diversity of membership enhances its capacity for…
As announced on December 18 by the Government of Canada, CADTH will become the Canada's Drug Agency (CDA-AMC).
We are excited and humbled by this opportunity. It builds on the trust we have established within the pan-Canadian drugs and devices environment, and our strong history of providing health…
December 18, 2023 | Ottawa, Ontario | Health Canada
Helping make Canada's drug system more sustainable and better prepared for the future
Canadians should be able to appropriately access and afford the prescription drugs they need. However, many Canadians are left vulnerable due to high drug costs…
CADTH has released a preview of the results from its Canadian Medical Imaging Inventory (CMII) survey, a national survey of imaging facilities across Canada. The Evidence Preview report offers a snapshot of the state of Canada’s advanced medical imaging capacity, which includes CT units, MRI units…
CADTH has published new evidence and guidance on the issue of emergency department (ED) overcrowding. The guidance comes as EDs in Canada continue coping with persistently higher patient volumes, staffing shortages and burnout, and as they brace for a potential influx of visits during respiratory…
It’s been 1 year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with evidence about drugs that have been approved and are already in use by people in Canada. With the PMDE program, CADTH is enhancing how we evaluate drugs across their life cycle and…